Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet-Reference-Cited by-同舟云学术

Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet

Published:2017-11 Issue: Volume:109 Page:S39-S46
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Helmlinger Gabriel,Al-Huniti Nidal,Aksenov Sergey^ORCID,Peskov Kirill^ORCID,Hallow Karen M.,Chu Lulu,Boulton David,Eriksson Ulf,Hamrén Bengt,Lambert Craig,Masson Eric,Tomkinson Helen,Stanski Donald

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference68 articles.

1. An integrated approach for inference and mechanistic modeling for advancing drug development;Aksenov;FEBS Lett.,2005

2. Physiological modeling of uric acid in man: application to assess benefit-risk of lesinurad in gout. 7th American Conference for Pharmacometrics (ACoP7). Seattle, USA;Aksenov;J. Pharmacokinet. Pharmacodyn.,2016

3. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients;Al-Huniti;Br. J. Clin. Pharmacol.,2016

4. Population exposure-response modeling of naloxegol in patients with noncancer-related pain and opioid-induced constipation;Al-Huniti;CPT Pharmacometrics Syst. Pharmacol.,2016

5. Dynamic prediction of progression free survival (PFS) and overall survival (OS) in Non-Small Cell Lung Cancer (NSCLC) using tumor size: a longitudinal joint modeling approach;Al-Huniti,2017

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Explainable machine learning prediction of edema adverse events in patients treated with tepotinib;Clinical and Translational Science;2024-09

2. Advances in mechanobiological pharmacokinetic-pharmacodynamic models of osteoporosis treatment – Pathways to optimise and exploit existing therapies;Bone;2024-09

3. Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model;CPT: Pharmacometrics & Systems Pharmacology;2024-06-12

4. Building blocks needed for mechanistic modeling of bioprocesses: A critical review based on protein production by CHO cells;Metabolic Engineering Communications;2024-06

5. Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology;Drug Metabolism and Pharmacokinetics;2024-06